From Wikipedia, the free encyclopedia
Combination drug used during eye surgery
| Combination of | |
|---|---|
| Phenylephrine | Alpha-1 adrenergic receptor agonist |
| Ketorolac | Nonsteroidal anti-inflammatory |
| Clinical data | |
| Trade names | Omidria |
| AHFS/ Drugs.com | Monograph |
| License data | |
|
Routes of administration | Intraocular |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| KEGG | |
Phenylephrine/ketorolac, sold under the brand name Omidria, is a combination drug used during cataract surgery [3] or intraocular lens replacement to prevent intraoperative miosis and to reduce postoperative pain. [1] It contains phenylephrine and ketorolac. [1]
Phenylephrine/ketorolac was approved for medical use in the United States in May 2014, [4] and in the European Union in July 2015. [2]
References
- ^ a b c "Omidria- phenylephrine and ketorolac injection, solution, concentrate". DailyMed. 11 December 2017. Retrieved 17 April 2020.
- ^ a b "Omidria EPAR". European Medicines Agency (EMA). 17 September 2018. Retrieved 17 April 2020.
- ^ Lawuyi LE, Gurbaxani A (2015). "The clinical utility of new combination phenylephrine/ketorolac injection in cataract surgery". Clinical Ophthalmology. 9. Auckland, N.Z.: 1249–54. doi: 10.2147/OPTH.S72321. PMC 4506037. PMID 26203214.
- ^ "Drug Approval Package: Omidria (phenylephrine and ketorolac) Injection NDA #205388". U.S. Food and Drug Administration (FDA). 9 December 2014. Retrieved 17 April 2020.
External links
- "Ketorolac mixture with phenylephrine". Drug Information Portal. U.S. National Library of Medicine.
|
Receptor ( ligands) |
| ||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Enzyme ( inhibitors) |
| ||||||||||||||||||||||||||
| Others | |||||||||||||||||||||||||||
 | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
Retrieved from "
https://en.wikipedia.org/?title=Phenylephrine/ketorolac&oldid=1173736129"
Hidden categories:
- Articles with short description
- Short description matches Wikidata
- Use American English from July 2020
- All Wikipedia articles written in American English
- Use dmy dates from April 2020
- Drugs with non-standard legal status
- Chemical articles without CAS registry number
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without InChI source
- Articles without UNII source
- Articles containing unverified chemical infoboxes
- Drugs that are a combination of chemicals
- All stub articles
From Wikipedia, the free encyclopedia
Combination drug used during eye surgery
| Combination of | |
|---|---|
| Phenylephrine | Alpha-1 adrenergic receptor agonist |
| Ketorolac | Nonsteroidal anti-inflammatory |
| Clinical data | |
| Trade names | Omidria |
| AHFS/ Drugs.com | Monograph |
| License data | |
|
Routes of administration | Intraocular |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| KEGG | |
Phenylephrine/ketorolac, sold under the brand name Omidria, is a combination drug used during cataract surgery [3] or intraocular lens replacement to prevent intraoperative miosis and to reduce postoperative pain. [1] It contains phenylephrine and ketorolac. [1]
Phenylephrine/ketorolac was approved for medical use in the United States in May 2014, [4] and in the European Union in July 2015. [2]
References
- ^ a b c "Omidria- phenylephrine and ketorolac injection, solution, concentrate". DailyMed. 11 December 2017. Retrieved 17 April 2020.
- ^ a b "Omidria EPAR". European Medicines Agency (EMA). 17 September 2018. Retrieved 17 April 2020.
- ^ Lawuyi LE, Gurbaxani A (2015). "The clinical utility of new combination phenylephrine/ketorolac injection in cataract surgery". Clinical Ophthalmology. 9. Auckland, N.Z.: 1249–54. doi: 10.2147/OPTH.S72321. PMC 4506037. PMID 26203214.
- ^ "Drug Approval Package: Omidria (phenylephrine and ketorolac) Injection NDA #205388". U.S. Food and Drug Administration (FDA). 9 December 2014. Retrieved 17 April 2020.
External links
- "Ketorolac mixture with phenylephrine". Drug Information Portal. U.S. National Library of Medicine.
| α1 |
| ||||
|---|---|---|---|---|---|
| α2 |
| ||||
| β |
| ||||
|
Receptor ( ligands) |
| ||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Enzyme ( inhibitors) |
| ||||||||||||||||||||||||||
| Others | |||||||||||||||||||||||||||
|
| This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
Retrieved from "
https://en.wikipedia.org/?title=Phenylephrine/ketorolac&oldid=1173736129"
Hidden categories:
- Articles with short description
- Short description matches Wikidata
- Use American English from July 2020
- All Wikipedia articles written in American English
- Use dmy dates from April 2020
- Drugs with non-standard legal status
- Chemical articles without CAS registry number
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without InChI source
- Articles without UNII source
- Articles containing unverified chemical infoboxes
- Drugs that are a combination of chemicals
- All stub articles